{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:40:37Z","timestamp":1784133637732,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diabetic Kidney Disease (DKD) is the leading cause of End Stage Renal Disease (ESRD). Arginine Vasopressin (AVP) plays pivotal roles in osmoregulation and renal water conservation. As patients with DKD are prone to develop osmotic irregularities, AVP is therefore, a potential pathophysiological target for disruption. Copeptin, a surrogate marker of AVP, is preferred over AVP due to comparatively greater stability and longer half-life. The study is designed to correlate the copeptin levels among subjects with Type 2 Diabetes Mellitus (DM) with worsening renal outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>It was a comparative cross-sectional study on 120 subjects with T2DM who were stratified into progressive deteriorating stages of chronic kidney disease (CKD) as per NKF KDOQI guidelines. Different biochemical variables HbA1c, serum BUN, serum creatinine UACR and GFR were done from the affiliated lab. Serum copeptin levels were determined using Copeptin sandwich ELISA technique. Data was analyzed through Statistical Program for Social Sciences (SPSS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Out of the 120 subjects that were recruited for study, 30% of subjects (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200936) developed severely decreased kidney function with GFR less than 30mL\/min\/1.73m2. Copeptin levels were seen to be increased with progressive stages of albuminuria (175.8\u2009\u00b1\u2009148.4 pg\/ml, 221.2\u2009\u00b1\u2009213.1 pg\/ml and 385.3\u2009\u00b1\u2009288.4 pg\/ml at UACR stage 1, 2 and 3, respectively) with positive correlation i.e.\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.375, p\u2009=\u2009\u2264\u20090.001. It was also found to be negatively correlated with declining GFR i.e. from 195.8\u2009\u00b1\u2009174.1 pg\/ml at stage 1 CKD to 291.7\u2009\u00b1\u2009268.8 pg\/ml at stage 5 CKD (\n                      <jats:italic>r<\/jats:italic>\n                      = -0.409, p\u2009=\u2009\u2264\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Increase in serum copeptin levels from stage 1 to stage 5 of CKD suggest its predictive role in T2DM associated nephropathy, supporting its potential role as an early biomarker. Early detection may help delay ESRD progression through timely interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-026-04777-5","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T16:54:46Z","timestamp":1769792086000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictive role and clinical correlation of copeptin in patients with type 2 diabetes mellitus associated nephropathy approaching end-stage renal disease"],"prefix":"10.1186","volume":"27","author":[{"given":"Tooba","family":"Noor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zareen","family":"Kiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Tassaduq","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7458-8367","authenticated-orcid":false,"given":"Farina","family":"Hanif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"4777_CR1","doi-asserted-by":"crossref","unstructured":"Tonneijck L, Muskiet MH, Smits MM, van Bommel EJ, Heerspink HJ, VanRaalte DH, Joles JA. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol. 2017.","DOI":"10.1681\/ASN.2016060666"},{"issue":"3","key":"4777_CR2","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3390\/kidneydial2030038","volume":"2","author":"EK Hoogeveen","year":"2022","unstructured":"Hoogeveen EK. The epidemiology of diabetic kidney disease. Kidney Dial. 2022;2(3):433\u201342.","journal-title":"Kidney Dialysis"},{"issue":"5","key":"4777_CR3","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","volume":"102","author":"P Rossing","year":"2022","unstructured":"Rossing P, et al. Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence. Kidney Int. 2022;102(5):990\u20139.","journal-title":"Kidney Int"},{"key":"4777_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2337\/diacare.28.1.164","volume":"28","author":"JL Gross","year":"2005","unstructured":"Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28:164\u201376.","journal-title":"Diabetes Care"},{"issue":"5","key":"4777_CR5","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jdiacomp.2013.03.003","volume":"27","author":"A Mima","year":"2013","unstructured":"Mima A. Diabetic nephropathy: protective factors and a new therapeutic paradigm. J Diab Comp. 2013;27(5):526\u201330. ISSN 1056-8727.","journal-title":"J Diab Comp"},{"issue":"18","key":"4777_CR6","doi-asserted-by":"publisher","first-page":"10397","DOI":"10.1073\/pnas.96.18.10397","volume":"96","author":"P Bardoux","year":"1999","unstructured":"Bardoux P, Martin H, Ahloulay M, Schmitt F, Bouby N, Trinh-Tan-Tang MM. Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats. Proc Natl Acad Sci. 1999;96(18):10397\u2013402.","journal-title":"Proc Natl Acad Sci"},{"key":"4777_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1741-7015-10-7","volume":"10","author":"CH Nickel","year":"2012","unstructured":"Nickel CH, Bingisser R, Morgenthaler NG. The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department. BMC Med. 2012;10:7.","journal-title":"BMC Med"},{"issue":"2","key":"4777_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.tem.2007.11.001","volume":"19","author":"NG Morgenthaler","year":"2008","unstructured":"Morgenthaler NG, Struck J, Jochberger S, Dunser MW. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab. 2008;19(2):43\u20139.","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"4777_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/09537109777492","volume":"8","author":"T Wun","year":"1997","unstructured":"Wun T. Vasopressin and platelets: a concise review. Platelets. 1997;8(1):15\u201322.","journal-title":"Platelets"},{"issue":"6","key":"4777_CR10","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1210\/jc.2016-1113","volume":"101","author":"RR Ray","year":"2016","unstructured":"Ray RR, Boustany E, Bouby N, Potier L, Fumeron F, Mohammedi K, et al. Plasma Copeptin, AVP gene Variants, and incidence of type 2 diabetes in a cohort from the community. J Clin End Metab. 2016;101(6):2432\u20139.","journal-title":"J Clin End Metab"},{"issue":"9","key":"4777_CR11","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1210\/JC.2015-2362","volume":"100","author":"GS Wannamethee","year":"2015","unstructured":"Wannamethee GS, Welsh P, Papacosta O, Copeptin. Insulin Resistance, and risk of incident diabetes in older men. J Clin End Metab. 2015;100(9):3332\u20139.","journal-title":"J Clin End Metab"},{"key":"4777_CR12","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1007\/s00125-013-2922-0","volume":"56","author":"WE Boertien","year":"2013","unstructured":"Boertien WE, Riphagen IJ, Drion I, Alkhalaf A, Bakker SJ, Groenier KH, et al. Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33). Diabetologia. 2013;56:1680\u201388.","journal-title":"Diabetologia"},{"issue":"1","key":"4777_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.arcmed.2018.04.002","volume":"49","author":"MD Villela-Torres","year":"2018","unstructured":"Villela-Torres MD, Mendoza AEH, Garc\u00eda AG, Parades ARA, Lopez EG, Stenvikel P. Copeptin plasma levels are associated with decline of renal function in patients with type 2 diabetes mellitus. Arch Med Res. 2018;49(1):36\u201343.","journal-title":"Arch Med Res"},{"issue":"2","key":"4777_CR14","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1093\/ckj\/sfs008","volume":"5","author":"HR Geus","year":"2012","unstructured":"Geus HR, Betjes MG, Bakker J. Biomarkers for the prediction of acute kidney injury: a narrative review on current status and future challenges. Clin Kid J. 2012;5(2):102\u20138.","journal-title":"Clin Kid J"},{"issue":"3","key":"4777_CR15","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1152\/ajprenal.00004.2011","volume":"300","author":"S Bolisetty","year":"2011","unstructured":"Bolisetty S, Agarwal A. Urine albumin as a biomarker in acute kidney injury. Am J Ren Physiol. 2011;300(3):626\u20137.","journal-title":"Am J Ren Physiol"},{"issue":"4","key":"4777_CR16","first-page":"37","volume":"16","author":"G Nils","year":"2010","unstructured":"Nils G, Morgenthaler, Copeptin. A biomarker of cardiovascular and renal function. Congest Heart Fail. 2010;16(4):37\u201344.","journal-title":"Congest Heart Fail"},{"issue":"6","key":"4777_CR17","first-page":"845","volume":"12","author":"M Zandbergen","year":"2019","unstructured":"Zandbergen M, et al. Dialysate copeptin and peritoneal transport in incident PD patients. Clin Kidney J. 2019;12(6):845\u201352.","journal-title":"Clin Kidney J"},{"issue":"12","key":"4777_CR18","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1210\/jc.2014-2295","volume":"99","author":"R Roussel","year":"2014","unstructured":"Roussel R, Fezeu L, Marre M, Velho G, Fumeron F, Jungers P. Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease. J Clin End Metab. 2014;99(12):4656\u201363.","journal-title":"J Clin End Metab"},{"key":"4777_CR19","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/ijo.2012.88","volume":"37","author":"S Enhorning","year":"2013","unstructured":"Enhorning S, Bankir L, Bouby N, et al. Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmo diet and cancer study cardiovascular cohort. Int J Obes. 2013;37:598\u2013603.","journal-title":"Int J Obes"},{"key":"4777_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/ki.2009.397","volume":"77","author":"E Meijer","year":"2010","unstructured":"Meijer E, Bakker SJ, Halbesma N, de Jong PE, Struck J, Gansevoort RT. Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int. 2010;77:29\u201336.","journal-title":"Kidney Int"},{"issue":"2","key":"4777_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000488304","volume":"72","author":"S Enh\u00f6rning","year":"2018","unstructured":"Enh\u00f6rning S, Melander O. The vasopressin system in the risk of diabetes and cardiorenal Disease, and hydration as a potential lifestyle intervention. Ann Nutr Metab. 2018;72(2):21\u20137.","journal-title":"Ann Nutr Metab"},{"key":"4777_CR22","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1038\/s41598-017-02421-9","volume":"7","author":"K Al Rubeaan","year":"2017","unstructured":"Al Rubeaan K, Siddiqui K, Al Ghonaim MA, et al. Assessment of the diagnostic value of different biomarkers in relation to various stages of diabetic nephropathy in type 2 diabetic patients. Sci Rep. 2017;7:2684.","journal-title":"Sci Rep"},{"issue":"6","key":"4777_CR23","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3390\/biom15060845","volume":"15","author":"G Gazi","year":"2025","unstructured":"Gazi G, Cruciat RC, Leucuta D-C, Al Srouji N, Popa S-L, Ismaiel M, Dumitrascu DI, Ismaiel A. Copeptin as a biomarker in chronic kidney Disease\u2014a systematic review and meta-analysis. Biomolecules. 2025;15(6):845.","journal-title":"Biomolecules"},{"key":"4777_CR24","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.arcmed.2020.05.018","volume":"51","author":"T Noor","year":"2020","unstructured":"Noor T, Hanif F, Kiran Z, Rehman R, Khan MT, Haque Z, et al. Relation of copeptin with diabetic and renal function markers among patients with diabetes mellitus progressing towards diabetic nephropathy. Arch Med Res. 2020;51:548\u201355.","journal-title":"Arch Med Res"},{"issue":"12","key":"4777_CR25","first-page":"1792","volume":"5","author":"RM Hameed","year":"2011","unstructured":"Hameed RM, Kadim WA. Vasopressin contribute to the renal disorder in Insulin-Depending diabetes mellitus (IDDM). Aus J Basic App Sci. 2011;5(12):1792\u20136.","journal-title":"Aus J Basic App Sci"},{"key":"4777_CR26","first-page":"157","volume":"10","author":"T Noor","year":"2022","unstructured":"Noor T, Kiran Z, Ali A, Syed SB, Hanif F. Correlation of copeptin with osmolarity and electrolytes in diabetes mellitus: a tertiary center outpatient experience. Int J End Health Sci Res. 2022;10:157\u201366.","journal-title":"Int J End Health Sci Res"},{"key":"4777_CR27","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.2337\/dc13-0683","volume":"36","author":"G Velho","year":"2013","unstructured":"Velho G, Bouby N, Hadjadj S, Matallah N, Mohammedi K, Fumeron F. Plasma copeptin and renal outcomes in patientswith type 2 diabetes and albuminuria. Diabetes Care. 2013;36:3639\u201345.","journal-title":"Diabetes Care"},{"key":"4777_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s43162-023-00207-2","volume":"35","author":"NN El-Soudany","year":"2023","unstructured":"El-Soudany NN, Bessa SSED, Morad HA, et al. Plasma copeptin level in type 2 diabetic patients and its role in diabetic nephropathy. Egypt J Intern Med. 2023;35:31.","journal-title":"Egypt J Intern Med"},{"issue":"2","key":"4777_CR29","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2215\/CJN.04560510","volume":"6","author":"E Meijer","year":"2011","unstructured":"Meijer E, Bakker SJ, van der Jagt EJ, et al. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011;6(2):361\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"4777_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000439061","volume":"42","author":"R Roussel","year":"2015","unstructured":"Roussel R, Matallah N, Bouby N, El Boustany R, Potier L, Fumeron F, et al. Plasma copeptin and decline in renal function in a cohort from the community: the prospective D.E.S.I.R. Study. Am J Nephrol. 2015;42(2):107\u201314.","journal-title":"Am J Nephrol"},{"key":"4777_CR31","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.jdiacomp.2017.04.005","volume":"31","author":"RE Boustany","year":"2017","unstructured":"Boustany RE, Taveau C, Chollet C, Velho G, Bankir L, Gelas FA, et al. Antagonism of vasopressin V2 receptor improves albuminuria at the early stage of diabetic nephropathy in a mouse model of type 2 diabetes. J Diab Comp. 2017;31:929\u201332.","journal-title":"J Diab Comp"},{"key":"4777_CR32","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1210\/en.2004-1590","volume":"146","author":"T Miyazaki","year":"2005","unstructured":"Miyazaki T, Yamamura Y, Onogawa T, Seya M, Iwatsuka R, Mizukami A. Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia. Endocrinology. 2005;146:3037\u201343.","journal-title":"Endocrinology"},{"key":"4777_CR33","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/ki.2011.119","volume":"80","author":"MV Irazabel","year":"2011","unstructured":"Irazabel MV, Torres VE, Hogan MC, Glockner J, King BF, Oftsie TG. Short-term effects of Tolvaptan on renal function andvolume in patients with autosomal dominant polycystic kidney disease. Kidney Int. 2011;80:295\u2013301.","journal-title":"Kidney Int"},{"key":"4777_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jjcc.2012.08.020","volume":"61","author":"Y Matsue","year":"2013","unstructured":"Matsue Y, Suzuki M, Seya M, et al. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. J Cardiol. 2013;61:169\u201374.","journal-title":"J Cardiol"},{"key":"4777_CR35","doi-asserted-by":"crossref","unstructured":"Mima AA. Narrative review of diabetic kidney disease: previous and current evidence-based therapeutic approaches. Adv Ther. 2022;39:3488\u2013500.","DOI":"10.1007\/s12325-022-02223-0"},{"key":"4777_CR36","doi-asserted-by":"publisher","first-page":"115032","DOI":"10.1016\/j.biopha.2023.115032","volume":"165","author":"A Mima","year":"2023","unstructured":"Mima A, Nomura A, Fujii T. Current findings on the efficacy of incretin-based drugs for diabetic kidney disease: a narrative review. Biomed Pharmacother. 2023;165:115032.","journal-title":"Biomed Pharmacother"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04777-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04777-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04777-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:25:29Z","timestamp":1781630729000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04777-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4777"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04777-5","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Institutional Review Board (IRB) of Dow University of Health Sciences (DUHS), Ref.no. IRB-1145\/DUHS\/Approval\/2018 and an informed written consent was taken in native language from the patients or their attendants, whatever feasible at that time. Helsinki\u2019s principle was followed throughout the course of study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"145"}}